Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)

Pseudotumor cerebri — now more precisely termed idiopathic intracranial hypertension (IIH) when no secondary cause is identified, and grouped under the broader umbrella term pseudotumor cerebri syndrome (PTCS) that also includes cases with a genuinely identifiable secondary cause — is a disorder of elevated intracranial pressure (ICP) occurring without a mass lesion, hydrocephalus, or venous sinus thrombosis to explain it.^[1] It is, overwhelmingly, a disease of obese women of reproductive age: more than 93% of affected patients are obese, the median age at onset is 34 years, and the annual incidence among obese women of childbearing age specifically reaches roughly 20 per 100,000 — a striking, genuinely useful epidemiologic pattern that should raise suspicion the moment a patient fitting that profile presents with a new headache.^[2] This chapter is built around a single organizing idea that should reframe how every encounter is approached: headache is what brings the patient to the pharmacy or the clinic, but vision is what the treatment plan actually has to protect. Papilledema — swelling of the optic disc from the transmitted pressure — occurs in up to 95% of cases, and it is asymptomatic vision loss, not the headache, that causes permanent harm when the diagnosis or the treatment escalation is delayed.^[2] A second organizing idea, and this chapter's other centerpiece, is that a meaningful share of intracranial hypertension is not idiopathic at all: a specific, genuinely memorable list of medications — tetracycline-class antibiotics (especially minocycline), vitamin A and its retinoid relatives, recombinant growth hormone, and several others — can cause the identical clinical syndrome, and recognizing that list is one of the most concrete, high-value contributions a pharmacist can make to this diagnosis (see Risk Factors).^[3]

Papilledema: bilateral optic disc swelling from elevated intracranial pressure, with blurred disc margins and engorged, tortuous retinal vessels. Papilledema is present in up to 95% of idiopathic intracranial hypertension, but it can be graded from subtle to severe, and can occasionally be entirely absent — its absence does not exclude the diagnosis (see Assessment & Diagnosis). (Jonathan Trobe, MD, University of Michigan Kellogg Eye Center, "The Eyes Have It", CC BY 3.0, Wikimedia Commons)

Headache

Headache is the presenting complaint in the substantial majority of patients, and it is frequently the feature that dominates the clinical picture — daily or near-daily, often severe enough to be genuinely disabling, and lacking a single specific pattern that distinguishes it from migraine or tension-type headache on history alone.^[2] It can be worsened by the maneuvers that raise intracranial pressure further — lying flat, Valsalva, coughing, bending forward — and can wake a patient from sleep. This nonspecificity is itself a genuine diagnostic trap: a patient can be treated for presumed migraine for months while papilledema-driven optic nerve damage accumulates silently in the background, which is exactly why the eye exam belongs in the workup of any new, atypical, or progressively worsening headache in the classic epidemiologic group (obese women of reproductive age) rather than being reserved for patients who already report visual symptoms.

Papilledema

Papilledema — optic disc swelling specifically caused by elevated intracranial pressure — is the physical finding around which the entire diagnostic framework is built (see Assessment & Diagnosis), and is present in up to 95% of cases.^[2] It ranges from subtle disc-margin blurring that is easy to miss without dilated fundoscopy or fundus photography, to severe swelling with peripapillary hemorrhages, cotton-wool spots, and exudates — a spectrum commonly graded clinically using the Frisén scale (grade 0, normal, through grade 5, severe swelling with obscuration of major vessels). Higher-grade papilledema, and papilledema that fails to improve with treatment, both correlate with a greater risk of permanent visual loss, which is why serial, standardized documentation (ideally with fundus photography and optical coherence tomography, not just a written description) matters far more here than it does in most other headache-adjacent complaints (see Monitoring & Follow-Up).

Transient visual obscurations

Transient visual obscurations (TVOs) — brief, seconds-long episodes of graying, dimming, or complete blackout of vision in one or both eyes — are reported by a large share of patients and are a direct consequence of transient disc ischemia from the swollen nerve head. They are frequently positional, provoked by bending over, standing up quickly, or Valsalva, and while they are genuinely common and do not, on their own, indicate irreversible damage, their frequency is a useful marker of disease activity worth asking about explicitly and tracking over time.

Pulsatile tinnitus

Pulsatile (or "synchronous") tinnitus — a whooshing, rushing sound the patient hears in time with their own heartbeat — is reported by roughly 60% of patients and is considered the single most specific symptom of the condition, reflecting turbulent blood flow across a narrowed or externally compressed venous sinus.^[2] A simple, genuinely useful bedside maneuver is gentle jugular venous compression on the symptomatic side, which transiently abolishes the sound in true pulsatile tinnitus of this type — a distinguishing feature from the far more common, non-pulsatile, non-specific tinnitus that has nothing to do with intracranial pressure.

Sixth cranial nerve (abducens) palsy and other neurologic findings

Horizontal diplopia from a unilateral or bilateral sixth cranial nerve (abducens) palsy occurs in a meaningful minority of patients. This is a genuinely important "false localizing sign" — it results from the long, vulnerable intracranial course of the abducens nerve being stretched or compressed by elevated pressure generally, not from a lesion actually located along the nerve's path, and its presence does not change the diagnostic approach (see Assessment & Diagnosis). Beyond this, the neurologic examination should otherwise be normal; any other focal deficit, seizure, or altered level of consciousness is a red flag that points away from idiopathic disease and toward a structural lesion or another process entirely (see Red Flags for Referral). Neck, shoulder, and interscapular pain — sometimes radicular in character — is also reported by a minority of patients and is thought to reflect meningeal or nerve-root traction from elevated CSF pressure.

Visual field loss — the finding that matters most, and the one patients notice least

This is the single most important teaching point in this entire chapter: visual field loss in this condition is typically insidious, painless, and can progress to a genuinely severe degree before a patient spontaneously reports any visual complaint at all. The earliest, most common pattern is an enlarged physiologic blind spot, followed by an inferonasal field defect, and — without adequate treatment — progression toward generalized constriction of the visual field and, eventually, severe and sometimes irreversible vision loss. Relying on "the patient says their vision is fine" as reassurance is a genuine, well-documented error; the visual field must be formally, objectively tested (see Assessment & Diagnosis and Monitoring & Follow-Up) rather than inferred from symptoms.

Fulminant idiopathic intracranial hypertension

A distinct, higher-risk subgroup — fulminant IIH — presents with severe visual loss developing rapidly, within about four weeks of symptom onset, sometimes accompanied by markedly elevated opening pressures and severe papilledema at first presentation. This pattern behaves differently from typical, gradually progressive disease: the usual stepwise medical titration described in Choose Initial Treatment is too slow to reliably prevent severe, permanent vision loss, and recognizing this pattern early enough to fast-track surgical evaluation — rather than waiting to see whether acetazolamide "catches up" — is a genuinely consequential clinical decision (see Special Populations and Treatment Failure/Next Step).

The two demographic risk factors that define the classic phenotype

• Obesity — present in more than 93% of patients — and, independently, a recent increase in body weight (even a relatively modest gain, well short of frank obesity, is associated with increased risk), suggesting a genuine dose-response relationship between adiposity and intracranial pressure rather than a simple binary obese/non-obese distinction.^[2]
• Female sex and reproductive age (roughly the 20s to 40s) — the single most consistent demographic pattern described across the literature, with a median age at onset of 34 years.^[2]

Other secondary causes to exclude before accepting an idiopathic diagnosis

• Cerebral venous sinus thrombosis — excluded with MR venography as part of the standard neuroimaging workup (see Assessment & Diagnosis); this is the single most important non-drug secondary cause not to miss, since its own treatment (anticoagulation) is entirely different.
• Obstructive sleep apnea — a recognized aggravating and, in some patients, contributory factor, and worth screening for independently of weight (see Non-Pharmacologic Treatment).
• Chronic kidney disease, systemic lupus erythematosus, and other systemic inflammatory or endocrine conditions (Addison disease, hypoparathyroidism, polycystic ovary syndrome) have each been associated with secondary intracranial hypertension in case reports and smaller series, and are reasonable to consider when the classic demographic or drug-exposure pattern is absent.

• Rapidly progressive, severe vision loss developing over days to a few weeks (the fulminant pattern): a same-day emergency — do not wait for a standard outpatient ophthalmology appointment or for a trial of acetazolamide to take effect; this pattern needs expedited neuro-ophthalmology and neurosurgical involvement in parallel (see Special Populations).
• Any focal neurologic deficit, seizure, or altered level of consciousness: not typical for idiopathic disease — reconsider a mass lesion, cerebral venous sinus thrombosis, or another intracranial process, and pursue emergent neuroimaging rather than a routine outpatient workup.
• New headache and visual symptoms in a pregnant patient: needs the same urgent ophthalmologic and diagnostic workup as a non-pregnant patient — pregnancy does not lower the priority of ruling out papilledema and elevated ICP, and additionally raises pre-eclampsia/eclampsia on the differential (see Special Populations).
• Any patient-reported change in visual acuity, color vision, or peripheral vision, however mild: a genuine escalation trigger given how insidious visual field loss typically is — do not defer formal ophthalmologic assessment on the assumption that a mild complaint means mild disease.
• A patient recently started on a known causative medication (a tetracycline, a retinoid, growth hormone, or another agent from Risk Factors) who develops a new headache: warrants the same urgent fundoscopic and diagnostic evaluation as any other suspected case — the presence of a plausible drug cause does not make the underlying elevated-pressure process any less dangerous to the optic nerve.

The revised diagnostic criteria for pseudotumor cerebri syndrome

The modern, modified Dandy criteria — formally the revised diagnostic criteria for pseudotumor cerebri syndrome (PTCS) — require, for a definite diagnosis in a patient with papilledema: papilledema on examination; a normal neurologic examination other than cranial nerve abnormalities (a sixth-nerve palsy is allowed and does not exclude the diagnosis — see Recognize the Condition); neuroimaging (MRI, with MR venography in most patients) showing a normal brain without hydrocephalus, a mass, or a structural lesion, and without abnormal meningeal enhancement — the same imaging that also directly excludes cerebral venous sinus thrombosis; normal cerebrospinal fluid composition; and an elevated lumbar puncture opening pressure, measured with the patient relaxed in the lateral decubitus position, of more than 250 mm CSF in adults (or more than 280 mm CSF in children, with 250 mm CSF used in a non-sedated, non-obese child).^[1][2] Supportive but not required neuroimaging findings — an empty or partially empty sella, flattening of the posterior sclera, distension of the perioptic subarachnoid space, and transverse venous sinus stenosis — strengthen the diagnosis when present but are not themselves diagnostic.^[1] When papilledema is absent, the same diagnosis can still be made if a sixth-nerve palsy is present alongside the other criteria; without either papilledema or a sixth-nerve palsy, the diagnosis can only be suggested, not confirmed, and requires at least three of the supportive neuroimaging findings above.^[1]

Neuroimaging comes before the lumbar puncture, not after

MRI of the brain (with MR venography) should be obtained and reviewed before lumbar puncture is performed, both to exclude a mass lesion that would make lumbar puncture dangerous and to directly exclude cerebral venous sinus thrombosis — the single most important secondary cause not to miss, and one whose own treatment (anticoagulation) is entirely different from the management described in Choose Initial Treatment.

The lumbar puncture — technique matters

Opening pressure must be measured with the patient in the lateral decubitus position, legs extended and genuinely relaxed (not actively flexed against resistance, and not during a Valsalva maneuver or breath-holding), since a poorly performed or artifactually elevated measurement can produce a falsely elevated — or falsely reassuring — reading. CSF should also be sent for cell count, protein, and glucose; genuinely normal composition is part of the diagnostic criteria, and any abnormality should prompt reconsideration of an infectious, inflammatory, or malignant process rather than idiopathic disease.

Medication reconciliation belongs inside the diagnostic workup, not after it

Before a diagnosis of idiopathic (primary) disease is accepted, the patient's full medication list should be reviewed specifically against the agents in Risk Factors — this is not a peripheral detail but a core, integral step of arriving at an accurate diagnosis, since a case caused by a recently started tetracycline or retinoid is managed differently (see Choose Initial Treatment and Special Populations) from genuinely idiopathic disease, even though both meet the same PTCS diagnostic criteria on lumbar puncture and imaging.^[3]

The ophthalmologic workup that drives ongoing management

Beyond confirming papilledema on fundoscopy, formal quantitative assessment should include automated (Humphrey) visual field perimetry, optical coherence tomography of the retinal nerve fibre layer to objectively quantify disc edema, and baseline fundus photography for serial comparison — all three are what actually drive the treatment and escalation decisions in the sections that follow, not the headache itself (see Monitoring & Follow-Up).

• Preserve vision — the primary, non-negotiable treatment target, tracked objectively with visual fields and optical coherence tomography rather than inferred from symptoms (see Recognize the Condition and Monitoring & Follow-Up).
• Reduce intracranial pressure toward a level that halts papilledema progression and reverses active visual field loss.
• Identify and remove or substitute any causative medication, in coordination with the prescriber, rather than treating drug-induced disease purely with add-on pharmacotherapy.
• Achieve meaningful, sustained weight loss (a genuinely disease-modifying goal, not an adjunct to drug therapy) in patients with obesity or recent weight gain.
• Control headache as its own, separate axis of morbidity, recognizing that headache can persist even after papilledema and visual field loss have resolved.
• Recognize the fulminant, rapidly progressive phenotype early enough to fast-track surgical evaluation rather than relying on medical therapy alone to act quickly enough.

Weight loss — a genuinely disease-modifying intervention, not just supportive advice

Weight loss has long been described as the cornerstone of management for a reason: it is not merely adjunctive to drug therapy, it independently lowers intracranial pressure, and the evidence for this has grown considerably more rigorous over time.^[2] In the landmark placebo-controlled acetazolamide trial itself, both study arms — including the diet-alone, placebo arm — were enrolled in a supervised low-sodium weight-reduction program, and a subsequent randomized trial specifically comparing bariatric surgery against a structured community weight-management program in patients with active idiopathic intracranial hypertension found that bariatric surgery produced substantially greater and more durable weight loss and a correspondingly greater, sustained reduction in intracranial pressure at 12 months.^[4][5] In practice, this means a genuine, early, and structured weight-management referral — with bariatric surgery evaluation for eligible patients whose disease remains active despite standard measures — belongs in the initial treatment plan alongside pharmacotherapy, not as an afterthought raised only once drug therapy has already failed.

Acetazolamide — first-line pharmacotherapy

Acetazolamide, a carbonic anhydrase inhibitor that reduces cerebrospinal fluid production, is first-line pharmacotherapy on the strength of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): in patients with mild visual loss at baseline, acetazolamide added to a supervised low-sodium weight-reduction diet produced a modest but statistically significant improvement in visual field function (perimetric mean deviation) at 6 months compared with diet alone, alongside greater reductions in papilledema grade and in CSF opening pressure.^[4] A practical starting approach is 250 mg orally twice daily (or an extended-release formulation dosed once or twice daily), titrated upward over days to a couple of weeks as tolerated toward the higher doses used in the trial protocol — up to a maximum of 4 g/day if genuinely tolerated, though many patients achieve good control, and most patients in the trial were maintained, at a considerably lower dose.^[4] Counsel proactively, before the patient calls back alarmed. Paresthesias of the fingers, toes, and around the mouth are extremely common, dose-related, and not dangerous — they reflect the drug's carbonic-anhydrase-inhibiting mechanism, not an allergic reaction, and should not by themselves prompt discontinuation. A metallic or otherwise altered taste, particularly with carbonated beverages, is similarly common and benign. Fatigue and mild gastrointestinal upset are also expected. Genuinely worth monitoring for, rather than just mentioning, are metabolic acidosis and hypokalemia (periodic basic metabolic panel — see Monitoring & Follow-Up) and an increased risk of renal calculi.

The sulfonamide "allergy" question

Acetazolamide is a non-antibiotic sulfonamide, and the historical concern about cross-reactivity with antimicrobial sulfonamides (e.g., sulfamethoxazole) in a patient with a labelled "sulfa allergy" is now understood to be considerably weaker than once assumed — the antigenic determinants differ meaningfully between the antibiotic and non-antibiotic sulfonamide classes. This should not be used to reflexively withhold a genuinely first-line, vision-protecting therapy from a patient with a mild prior reaction (e.g., a rash) to a sulfonamide antibiotic; a case-by-case risk discussion, reserving real caution for patients with a history of a severe reaction such as Stevens-Johnson syndrome or toxic epidermal necrolysis, is the more accurate and more clinically useful approach.

Second-line and adjunct pharmacotherapy

Furosemide is a reasonable second-line or add-on diuretic option when acetazolamide alone is insufficient or not tolerated, though its supporting evidence base is considerably weaker than acetazolamide's. Topiramate is a genuinely useful alternative, particularly when headache has a migrainous quality or when the patient would benefit from its own independent weight-loss effect: it carries mild carbonic-anhydrase-inhibiting activity of its own in addition to its established migraine-preventive and appetite-suppressant properties, giving it a plausible dual mechanism in this specific condition.^[6] Topiramate carries its own, separate teratogenicity concern (oral clefts) and needs the same reproductive-health counselling given for any teratogenic agent in a woman of reproductive age (see Special Populations).

Corticosteroids — a short-term surgical bridge only, never maintenance therapy

Corticosteroids (e.g., a short oral dexamethasone course, or IV methylprednisolone in a hospitalized patient) have a narrow, specific role as a temporary bridge to lower intracranial pressure while awaiting definitive surgical intervention in fulminant or severely progressive disease — they are not appropriate as ongoing maintenance therapy. Chronic corticosteroid use is genuinely counterproductive here: it promotes further weight gain (working directly against the disease-modifying goal above) and can produce rebound intracranial hypertension when the dose is tapered or stopped (see Risk Factors), making an already difficult disease harder to control if used beyond a short, specialist-directed bridge.

• Refer promptly to a structured weight-management program (dietitian involvement, a supervised low-sodium, calorie-reduced diet) as active, disease-modifying treatment — not a lifestyle suggestion appended at the end of the visit.
• Discuss bariatric surgery evaluation for medically eligible patients whose disease remains active despite standard weight-management measures, given the substantially greater and more durable weight loss and intracranial-pressure reduction demonstrated against community weight management in a dedicated randomized trial.^[5]
• Identify and discontinue or substitute any causative medication (see Risk Factors) in direct coordination with the prescribing clinician — do not stop an essential therapy such as isotretinoin for severe cystic acne or lithium for bipolar disorder unilaterally; work out an alternative or a bridging plan together.
• Screen for and treat obstructive sleep apnea when present, given its recognized role as an aggravating factor independent of weight.
• Arrange serial, standardized visual field testing and optical coherence tomography rather than relying on symptom review alone to judge disease activity (see Monitoring & Follow-Up).
• Manage headache as its own problem once the underlying pressure is being addressed, and actively avoid medication-overuse headache from frequent as-needed analgesic use.

Pregnancy

Pregnancy does not fundamentally change the diagnostic urgency or approach described above — a pregnant patient with new headache and visual symptoms in the classic pattern still needs the same fundoscopic and, when indicated, lumbar-puncture-based workup, alongside consideration of pre-eclampsia/eclampsia on the differential (see Red Flags for Referral). Acetazolamide has historically been used cautiously in pregnancy, reflecting an older signal of limb-reduction defects in high-dose animal studies; accumulating human observational data have been reassuring, and many centres now use it when the benefit of protecting vision clearly outweighs the residual theoretical risk, particularly beyond the first trimester — this is a genuine shared, specialist-directed decision rather than a default avoidance. Topiramate, by contrast, carries a better-established human teratogenicity signal (oral clefts) and is generally avoided in pregnancy where an alternative exists. Structured weight-loss intervention is deferred until after delivery. Surgical options are reserved for vision-threatening or fulminant presentations, as they would be outside pregnancy, with obstetric input on timing and anesthesia considerations.

Pediatrics

The disease looks meaningfully different in children, especially prepubertal children: the strong female predominance and obesity association seen in adults are considerably less consistent before puberty, and a secondary cause — most notably growth hormone therapy or, less commonly, another agent from Risk Factors — should be actively sought rather than assumed absent.^[3] The lumbar puncture opening pressure threshold used for diagnosis also differs from the adult cutoff (see Assessment & Diagnosis). Children on growth hormone therapy who develop a new headache warrant a low threshold for fundoscopic screening given the recognized association. The same vision-protective priorities and monitoring intensity described throughout this chapter apply regardless of age.

Fulminant disease

Fulminant idiopathic intracranial hypertension — severe visual loss developing within about four weeks of symptom onset — should not be managed on the standard stepwise medical-therapy timeline described in Choose Initial Treatment, because that timeline is built around gradual dose titration that is too slow to reliably prevent severe, permanent visual loss in this specific presentation. Expedited neuro-ophthalmology and neurosurgical evaluation, a short corticosteroid bridge where directed by the treating specialist, and early surgical intervention (see Non-Pharmacologic Treatment) should proceed in parallel with — not sequentially after — a trial of maximal medical therapy.

Drug-induced and secondary disease

Once a plausible causative agent from Risk Factors is identified, the central management step is discontinuing or substituting that agent in direct coordination with the prescribing clinician, rather than simply adding acetazolamide on top of a drug that continues to drive the underlying process.^[3] Resolution can lag meaningfully behind discontinuation — do not assume the process is finished the moment the drug is stopped, and continue the same standard visual monitoring described in Monitoring & Follow-Up until papilledema and visual field findings have genuinely normalized, not just until symptoms have improved. If findings fail to improve after a reasonable period following discontinuation, reconsider whether the patient in fact has coincidental idiopathic disease that happens to have appeared around the same time as the medication exposure, and manage accordingly (see Treatment Failure/Next Step).

• Obtain formal, automated visual field perimetry at baseline and at every follow-up visit while disease is active; space visits further apart only once the visual fields, papilledema grade, and opening-pressure-driving symptoms have been stable for a sustained period.
• Track optical coherence tomography of the retinal nerve fibre layer and serial fundus photography alongside perimetry — together, these three objective measures, not the headache history, are what should drive escalation or de-escalation decisions (see Treatment Failure/Next Step).
• Check a basic metabolic panel periodically in any patient on acetazolamide (or acetazolamide plus topiramate or furosemide) to monitor for metabolic acidosis and hypokalemia, and ask directly about flank pain or other symptoms of renal calculi.
• Track weight trend and engagement with the weight-management program as an active treatment metric, not an incidental data point.
• Keep a headache diary or equivalent tracking, and specifically screen for medication-overuse headache developing from frequent as-needed analgesic use.
• Reconcile medications at every visit specifically for newly added agents from Risk Factors — a genuinely easy, high-value check that is simple to miss once a patient is established in a monitoring routine.
• In pregnancy, coordinate visual and pressure-related monitoring jointly with obstetrics rather than as an entirely separate track (see Special Populations).

1. Inadequate visual field or papilledema response on maximally tolerated acetazolamide: add or switch to furosemide or topiramate, and intensify the weight-management intervention (including bariatric surgery evaluation) rather than simply continuing the same regimen unchanged.^[5]
2. Continued visual field progression despite optimized medical therapy and weight management: refer for surgical evaluation — optic nerve sheath fenestration, CSF shunting, or venous sinus stenting depending on the clinical picture and, where relevant, venographic findings (see Non-Pharmacologic Treatment).^[7]
3. A documented focal venous sinus stenosis with a significant trans-stenosis pressure gradient on catheter venography: consider venous sinus stenting specifically, rather than defaulting to shunting or fenestration.^[7]
4. Rapidly progressive, severe vision loss at any point (the fulminant pattern): do not wait for medical therapy to demonstrate effect — escalate immediately to urgent surgical referral, with a short corticosteroid bridge where specialist-directed (see Special Populations).
5. A presumed drug-induced case that fails to improve within a reasonable period after discontinuing the causative agent: reconsider a coincidental diagnosis of idiopathic disease and manage with the same escalation pathway as any other case, rather than continuing to attribute ongoing findings to a drug that has already been stopped.
6. Recurrent or refractory disease following surgical intervention: pursue multidisciplinary reassessment, including repeat neuroimaging (to exclude an evolving venous sinus thrombosis or stent-adjacent restenosis) rather than assuming the original diagnosis and treatment plan remain adequate unchanged.

• Treating headache severity as the primary marker of disease activity and treatment adequacy, rather than the objective visual findings that actually determine long-term outcome (see Treatment Targets).
• Reassuring a patient because they report no visual symptoms, without formal visual field testing — visual field loss in this condition is characteristically insidious and can be substantial before it is subjectively noticed (see Recognize the Condition).
• Performing or ordering a lumbar puncture before neuroimaging has excluded a mass lesion and, specifically, cerebral venous sinus thrombosis.
• Skipping medication reconciliation against the drug-induced causes in Risk Factors at the time of diagnosis, and only considering it later if standard therapy fails to work as expected.
• Reflexively withholding acetazolamide from a patient with a mild, non-severe "sulfa allergy" label without an individualized risk discussion (see Choose Initial Treatment).
• Mistaking acetazolamide's expected paresthesias or taste disturbance for an allergic reaction and stopping a genuinely effective, first-line, vision-protecting therapy as a result.
• Using chronic oral corticosteroids as maintenance therapy — this promotes the weight gain the rest of the treatment plan is working against and risks rebound intracranial hypertension on withdrawal (see Choose Initial Treatment).
• Treating the fulminant, rapidly progressive phenotype on the same gradual medical-titration timeline as typical disease, rather than fast-tracking surgical evaluation (see Special Populations).
• Prescribing topiramate to a woman of reproductive potential without an explicit teratogenicity and contraception discussion.
• Discontinuing a causative medication unilaterally, without coordinating an alternative or a bridging plan with the prescribing clinician, in a patient on an essential therapy (isotretinoin for severe acne, lithium for bipolar disorder).
• Treating weight loss as a vague lifestyle suggestion appended at the end of the visit rather than as an active, evidence-based, disease-modifying component of the treatment plan in its own right (see Choose Initial Treatment).
• Assuming a drug-induced case is fully resolved the moment the causative medication is stopped, rather than continuing standard visual monitoring until objective findings normalize (see Special Populations).

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

First-Line Pharmacotherapy

Acetazolamide, added to a supervised weight-reduction program, is first-line pharmacotherapy on the strength of the placebo-controlled Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Second-Line and Adjunct Pharmacotherapy

Used when acetazolamide alone is insufficient or not tolerated, or when a dual-purpose agent is desirable.

Short-Term Surgical Bridge (Specialist-Directed)

Reserved for fulminant or rapidly progressive disease while definitive surgical treatment is arranged — never used as chronic maintenance therapy.

Medications and Agents Associated With Secondary Intracranial Hypertension

Not a treatment table — a genuinely pharmacist-relevant medication-reconciliation reference. Confirming or excluding one of these exposures is an integral part of the diagnostic workup (see Assessment & Diagnosis), and management centers on discontinuing or substituting the agent in coordination with the prescriber, not simply adding standard pharmacotherapy on top of it (see Special Populations).